Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii

Malin Graffner-Nordberg, Karin Kolmodin, Johan Åqvist, Sherry Queener, Anders Hallberg

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A series of dihydrofolate reductase (DHFR) inhibitors, where the methylenamino-bridge of non-classical inhibitors was replaced with an ester function, have been prepared as potential soft drugs intended for inhalation against Pneumocystis carinii pneumonia (PCP). Several of the new ester-based inhibitors that should serve as good substrates for the ubiquitous esterases and possibly constitute safer alternatives to metabolically stable DHFR inhibitors administered orally, were found to be potent inhibitors of P. carinii DHFR (pcDHFR). Although the objectives of the present program is to achieve a favorable toxicity profile by applying the soft drug concept, a high preference for inhibition of the fungal DHFR versus the mammalian DHFR is still desirable to suppress host toxicity at the site of administration. Compounds with a slight preference for the fungal enzyme were identified. The selection of the target compounds for synthesis was partly guided by an automated docking and scoring procedure as well as molecular dynamics simulations. The modest selectivity of the synthesized inhibitors was reasonably well predicted, although a correct ranking of the relative affinities was not successful in all cases.

Original languageEnglish
Pages (from-to)43-53
Number of pages11
JournalEuropean Journal of Pharmaceutical Sciences
Volume22
Issue number1
DOIs
StatePublished - May 2004

Fingerprint

Folic Acid Antagonists
Pneumocystis carinii
Tetrahydrofolate Dehydrogenase
Esters
Inhalation Administration
Pharmaceutical Preparations
Pneumocystis Pneumonia
Esterases
Molecular Dynamics Simulation
Enzymes

Keywords

  • Dihydrofolate reductase
  • Molecular dynamics
  • Pneumocystis carinii
  • Soft drug

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. / Graffner-Nordberg, Malin; Kolmodin, Karin; Åqvist, Johan; Queener, Sherry; Hallberg, Anders.

In: European Journal of Pharmaceutical Sciences, Vol. 22, No. 1, 05.2004, p. 43-53.

Research output: Contribution to journalArticle

@article{e2c14dabdbbc4c3aa00f97450abdecbf,
title = "Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii",
abstract = "A series of dihydrofolate reductase (DHFR) inhibitors, where the methylenamino-bridge of non-classical inhibitors was replaced with an ester function, have been prepared as potential soft drugs intended for inhalation against Pneumocystis carinii pneumonia (PCP). Several of the new ester-based inhibitors that should serve as good substrates for the ubiquitous esterases and possibly constitute safer alternatives to metabolically stable DHFR inhibitors administered orally, were found to be potent inhibitors of P. carinii DHFR (pcDHFR). Although the objectives of the present program is to achieve a favorable toxicity profile by applying the soft drug concept, a high preference for inhibition of the fungal DHFR versus the mammalian DHFR is still desirable to suppress host toxicity at the site of administration. Compounds with a slight preference for the fungal enzyme were identified. The selection of the target compounds for synthesis was partly guided by an automated docking and scoring procedure as well as molecular dynamics simulations. The modest selectivity of the synthesized inhibitors was reasonably well predicted, although a correct ranking of the relative affinities was not successful in all cases.",
keywords = "Dihydrofolate reductase, Molecular dynamics, Pneumocystis carinii, Soft drug",
author = "Malin Graffner-Nordberg and Karin Kolmodin and Johan {\AA}qvist and Sherry Queener and Anders Hallberg",
year = "2004",
month = "5",
doi = "10.1016/j.ejps.2004.02.004",
language = "English",
volume = "22",
pages = "43--53",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii

AU - Graffner-Nordberg, Malin

AU - Kolmodin, Karin

AU - Åqvist, Johan

AU - Queener, Sherry

AU - Hallberg, Anders

PY - 2004/5

Y1 - 2004/5

N2 - A series of dihydrofolate reductase (DHFR) inhibitors, where the methylenamino-bridge of non-classical inhibitors was replaced with an ester function, have been prepared as potential soft drugs intended for inhalation against Pneumocystis carinii pneumonia (PCP). Several of the new ester-based inhibitors that should serve as good substrates for the ubiquitous esterases and possibly constitute safer alternatives to metabolically stable DHFR inhibitors administered orally, were found to be potent inhibitors of P. carinii DHFR (pcDHFR). Although the objectives of the present program is to achieve a favorable toxicity profile by applying the soft drug concept, a high preference for inhibition of the fungal DHFR versus the mammalian DHFR is still desirable to suppress host toxicity at the site of administration. Compounds with a slight preference for the fungal enzyme were identified. The selection of the target compounds for synthesis was partly guided by an automated docking and scoring procedure as well as molecular dynamics simulations. The modest selectivity of the synthesized inhibitors was reasonably well predicted, although a correct ranking of the relative affinities was not successful in all cases.

AB - A series of dihydrofolate reductase (DHFR) inhibitors, where the methylenamino-bridge of non-classical inhibitors was replaced with an ester function, have been prepared as potential soft drugs intended for inhalation against Pneumocystis carinii pneumonia (PCP). Several of the new ester-based inhibitors that should serve as good substrates for the ubiquitous esterases and possibly constitute safer alternatives to metabolically stable DHFR inhibitors administered orally, were found to be potent inhibitors of P. carinii DHFR (pcDHFR). Although the objectives of the present program is to achieve a favorable toxicity profile by applying the soft drug concept, a high preference for inhibition of the fungal DHFR versus the mammalian DHFR is still desirable to suppress host toxicity at the site of administration. Compounds with a slight preference for the fungal enzyme were identified. The selection of the target compounds for synthesis was partly guided by an automated docking and scoring procedure as well as molecular dynamics simulations. The modest selectivity of the synthesized inhibitors was reasonably well predicted, although a correct ranking of the relative affinities was not successful in all cases.

KW - Dihydrofolate reductase

KW - Molecular dynamics

KW - Pneumocystis carinii

KW - Soft drug

UR - http://www.scopus.com/inward/record.url?scp=2142647173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142647173&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2004.02.004

DO - 10.1016/j.ejps.2004.02.004

M3 - Article

C2 - 15113582

AN - SCOPUS:2142647173

VL - 22

SP - 43

EP - 53

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

IS - 1

ER -